VeroScience LLC develops and markets biotechnology and healthcare products. The firm also develops novel, practical, and effective therapies for chronic debilitating human diseases such as Type 2 diabetes, metabolic syndrome, autoimmune disease, and cancer through interdisciplinary basic research. The company was founded by Anthony H. Cincotta in 2001 and is headquartered in Tiverton, RI.

Sells nutritional based chocolate snacks through online

Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD.

Aventis Pharma Deutschland GmbH produces pharmaceutical products. It offers prescription drugs, human vaccines, and therapeutic proteins businesses. Aventis Pharma Deutschland plans and designs plants and process control systems in the areas of active ingredients production and finished drugs. The company is headquartered in Frankfurt am Main, Germany.

Cambridge Isotope Laboratories, Inc. produces stable isotope labeled compounds. It offers deuterated NMR solvents, gases, amino acids, Bio-Express Cell Growth Media, forensic standards, RNA/DNA products, metabolites, fatty acids, sugars, metals, NMR reference standards, buffers and environmental contaminant standards. The company was founded by Joel C. Bradley in 1981 and is headquartered in Tewksbury, MA.

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

Sanofi is a global healthcare company. Among their duties are researching disease causes, determining starting points for drug treatment, developing drugs, producing active ingredients, and delivering finished drugs and active ingredients. Specialists in vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases, and consumer healthcare.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's, and Crohn's diseases. The Company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.

Enprani Co., Ltd., part of Korea Cast Iron Pipe Ind. Co., Ltd., is a South Korean company located in Inchon. The firm manufactures and sells cosmetic products.

Benz Biotechnology (Yunnan) Co., Ltd., established on 2004-12-13, Business scope includes biotechnology pharmaceuticals,API,Chinese herbal medicine products and anti-cancer health products,Research on Health Food,to develop.(Except for national prohibitions and restrictions.Business scope involving a license is operated according to a license).

Pharnext is an advanced clinical-stage biopharmaceutical company founded in April 2007 by renowned scientists and entrepreneurs including Professor Daniel Cohen and collaborators, pioneers in modern genomics. The company develops new therapeutics for neurodegenerative diseases - orphan and common – where there are currently no cures and existing therapies available. Pharnext is the pioneer of a new paradigm for the discovery of medicinal drugs: PLEOTHERAPY™. The R&D approach protected by Pharnext systemizes new uses of approved drugs. It is based on network pharmacology utilizing complex and extensive genomic data to identify the thousands of molecules possibly involved in a disease. From this disease molecular network, Pharnext deduces synergistic combinations of drugs already approved but for unrelated indications. These novel therapeutics called PLEODRUG™ are then developed at new optimal doses and under new formulations. They offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The proof of concept of the PLEOTHERAPY approach was obtained with PLEODRUG PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) through positive and consistent Phase 2 and Phase 3 results. PLEODRUG PXT864 generated encouraging Phase 2 data in Alzheimer’s disease. They also plan to develop the same agent in other orphan and common neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS).